Charles River Laboratories (CRL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $16.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Charles River Laboratories (CRL) Financials: Revenue, Profit and Cash Flow
Charles River Laboratories reported revenue of $4.02B for the fiscal year ended Dec 31, 2025, down 0.9% from the year before. That year, net income was -$142.16M with a net margin of -3.5%, operating cash flow was $737.65M and free cash flow was $518.49M. The quarter ended Sep 30, 2026 had revenue of $982.73M and net income of $334.44M.
Revenue and Margins
The operating margin was 0.6% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.68B, a compound annual rate of 10.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.02B | -0.9% | 33.0% | 0.6% | -3.5% |
| Dec 2024 | $4.05B | -1.9% | 32.9% | 5.6% | 0.6% |
| Dec 2023 | $4.13B | +3.9% | 36.4% | 14.9% | 11.6% |
| Dec 2022 | $3.98B | +12.3% | 36.8% | 16.4% | 12.4% |
| Dec 2021 | $3.54B | +21.1% | 37.7% | 16.7% | 11.3% |
| Dec 2020 | $2.92B | +11.5% | 36.7% | 14.8% | 12.5% |
| Dec 2019 | $2.62B | +15.7% | 36.6% | 13.4% | 9.7% |
| Dec 2018 | $2.27B | +22.0% | 37.1% | 14.6% | 10.1% |
| Dec 2017 | $1.86B | +10.5% | 37.7% | 15.5% | 6.8% |
| Dec 2016 | $1.68B | N/A | 38.3% | 14.1% | 9.3% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income rose 501.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B |
| Cost of revenue | $2.69B | $2.72B | $2.63B | $2.51B | $2.21B | $1.85B | $1.66B | $1.43B | $1.16B | $1.04B |
| Gross profit | $1.32B | $1.33B | $1.50B | $1.46B | $1.33B | $1.07B | $958.31M | $840.07M | $700.92M | $643.96M |
| Operating income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M | $432.73M | $351.15M | $331.38M | $288.28M | $237.55M |
| Net income | -$142.16M | $25.29M | $480.37M | $492.61M | $398.84M | $365.31M | $254.06M | $228.72M | $125.45M | $156.37M |
| EBITDA | $405.90M | $572.57M | $1.03B | $985.37M | $819.51M | $767.64M | $561.54M | $506.42M | $457.20M | $375.97M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $982.73M | $1.00B | $995.83M | $994.23M | $1.00B | $1.03B | $984.17M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B |
| Gross profit | $357.87M | $363.37M | $294.66M | $309.68M | $338.79M | $357.07M | $317.73M | $284.24M | $349.02M | $353.71M | $344.84M | $364.08M |
| Operating income | $202.64M | $119.89M | $119.90M | -$283.44M | $133.80M | $100.13M | $74.67M | -$167.69M | $117.41M | $151.65M | $125.98M | $132.92M |
| Net income | $334.44M | -$760.00K | -$14.80M | -$276.29M | $55.56M | $52.69M | $25.88M | -$213.75M | $70.30M | $94.26M | $74.48M | $188.95M |
Balance Sheet
As of Dec 2025, total debt of $2.20B exceeded cash and equivalents by $1.98B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B |
| Current assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $897.84M | $826.63M | $656.83M |
| Cash and equivalents | $213.77M | $194.61M | $276.77M | $233.91M | $241.21M | $228.42M | $238.01M | $195.44M | $163.79M | $117.63M |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B |
| Short-term debt | $61.06M | $114.02M | $441.12M | $50.20M | $36.06M | $50.21M | $38.55M | $31.42M | $31.00M | $27.31M |
| Long-term debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.93B | $1.85B | $1.64B | $1.11B | $1.21B |
| Shareholder equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $836.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.45B | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B |
| Total liabilities | $4.18B | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | $4.54B |
| Cash and equivalents | $200.38M | $192.03M | $191.83M | $213.77M | $207.10M | $182.82M | $229.36M | $194.61M | $210.17M | $179.21M | $327.04M | $276.77M |
| Shareholder equity | $3.23B | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | $3.60B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 70.3% of operating cash flow. Share repurchases came to 69.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | $760.80M | $546.58M | $480.94M | $441.14M | $318.07M | $316.90M |
| Capital expenditures | $219.15M | $232.97M | $318.53M | $324.73M | $228.77M | $166.56M | $140.51M | $140.05M | $82.43M | $55.29M |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | $532.03M | $380.01M | $340.42M | $301.09M | $235.64M | $261.61M |
| Dividends paid | N/A | N/A | $25.60M | N/A | $45.65M | $46.59M | $34.55M | N/A | $0 | $0 |
| Share repurchases | $360.67M | $119.17M | $24.16M | $38.65M | $40.71M | $23.98M | $18.09M | $13.85M | $106.91M | $12.27M |
| Investing cash flow | -$209.32M | -$245.09M | -$563.15M | -$607.92M | -$1.44B | -$601.54M | -$681.50M | -$955.00M | -$72.59M | -$692.67M |
| Financing cash flow | -$536.73M | -$550.93M | -$85.52M | -$42.40M | $672.60M | $47.25M | $231.94M | $558.06M | -$208.48M | $380.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.09M | $179.72M | $41.08M | $147.52M | $213.83M | $204.60M | $171.70M | $159.36M | $251.79M | $193.53M | $129.89M | $220.94M |
| Capital expenditures | $46.81M | $31.11M | $55.91M | $88.95M | $35.58M | $35.30M | $59.32M | $75.62M | $38.72M | $39.49M | $79.14M | $78.32M |
| Free cash flow | $207.28M | $148.62M | -$14.83M | $58.57M | $178.25M | $169.31M | $112.37M | $83.75M | $213.07M | $154.05M | $50.74M | $142.62M |
Frequently Asked Questions About CRL
What is Charles River Laboratories' annual revenue?
Charles River Laboratories reported revenue of $4.02B for the fiscal year ended Dec 31, 2025.
How fast is Charles River Laboratories' revenue growing?
Revenue was down 0.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.
Is Charles River Laboratories profitable?
No. Charles River Laboratories reported net income of -$142.16M for the fiscal year ended Dec 31, 2025, with a net margin of -3.5%.
How much free cash flow does CRL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $737.65M minus capital expenditures of $219.15M produced free cash flow of $518.49M.
How much debt does Charles River Laboratories have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $2.14B, short-term debt of $61.06M and cash and equivalents of $213.77M.
CRL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts